Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
MapLight Therapeutics prices $250m Nasdaq IPO at $17 a share as biotech listings rebound
Find out how MapLight Therapeutics’ $250 million Nasdaq IPO is reigniting biotech investor sentiment and funding its next wave of CNS drug trials.
Novartis makes $12bn bet on RNA medicine with Avidity Biosciences acquisition to expand rare-disease pipeline
Find out why Novartis’s $12 billion Avidity Biosciences deal marks a turning point for big pharma’s RNA-therapy ambitions.
Fate Therapeutics unveils ACR 2025 results: FT819 off-the-shelf CAR T drives immune remodeling in lupus
Discover how Fate Therapeutics’ FT819 off-the-shelf CAR T therapy is reshaping lupus treatment through durable immune remodeling and long-term remission.
Why fall is becoming a difficult season for people with asthma and COPD—and what VARON suggests
Fall air can trigger breathing issues. Discover how VARON oxygen solutions support respiratory wellness at home and on the go this season.
Is Immuron (ASX: IMC) quietly staging a turnaround? PROIBS launch sparks 20% rally
Immuron (ASX: IMC) shares jumped 20 percent following its IBS product launch. Can the PROIBS rollout turn this microcap into a digestive health contender?
Novartis is buying its way into the next wave of genetic medicine — Avidity could be the entry point
Discover how Novartis’s proposed acquisition of Avidity Biosciences at over $70 a share could reshape its pipeline strategy and disrupt the rare-disease biotech space.
Can Bristol Myers Squibb’s CD19 NEX-T therapy replace lifelong immunosuppression? Early Phase 1 data raises the question
Bristol Myers Squibb’s new CAR T data suggests immune reset potential in lupus, systemic sclerosis, and inflammatory myopathies. Read how the paradigm may shift.
Interpreting the RESET-RA 12-month outcomes: What matters for clinical decision-making
Find out how SetPoint Medical’s neuroimmune modulation therapy is reshaping rheumatoid arthritis treatment with sustained 12-month clinical results.
How Northwest Biotherapeutics’ acquisition of Advent BioServices may reshape its cell therapy strategy
Northwest Biotherapeutics acquires Advent BioServices to scale DCVax production and integrate UK manufacturing. Find out what this means for its immunotherapy pipeline.
Incyte’s Opzelura delivers Phase 3b win in moderate adult atopic dermatitis patients
Incyte’s Opzelura cream shows strong Phase 3b results in adults with moderate atopic dermatitis. Find out what this could mean for EU filings and future growth.